Back to top
more

Sage Therapeutics (SAGE)

(Delayed Data from NSDQ)

$6.05 USD

6.05
1,060,671

-0.03 (-0.49%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $6.06 +0.01 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline

by Zacks Equity Research

United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

by Zacks Equity Research

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.

Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -4.22% and 38.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Sage and Biogen's NDA for Depression Drug Gets Priority Review

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.

Zacks Investment Ideas feature highlights: XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB

by Zacks Equity Research

XBI, Catalyst Pharma, Prometheus Biosciences, Sage Therapeutics and IBB are part of the Zacks Investment Ideas article.

Andrew Rocco headshot

Biotech's Blockbuster Week: 3 Stocks to Watch

by Andrew Rocco

In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.

Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?

by Zacks Equity Research

Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Ideas feature highlights: ATAI Life Sciences, Biogen and Sage

by Zacks Equity Research

ATAI Life Sciences, Biogen and Sage have been highlighted in this Investment Ideas article.

Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression

by Zacks Equity Research

Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.

Andrew Rocco headshot

3 Biotech Stocks Aiming to Reinvent Mental Health Treatment

by Andrew Rocco

Atai, Biogen, and Sage are working to develop new treatments for mental illness.

Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of -6.94% and 3.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?

by Zacks Equity Research

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.

Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for EES

Is WisdomTree U.S. SmallCap ETF (EES) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for EES

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 1.39% and 14.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sage (SAGE), Biogen (BIIB) Depression Drug Meets Study Goals

by Zacks Equity Research

Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a phase III study, which evaluated zuranolone to treat postpartum depression in women.

Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB

by Zacks Equity Research

Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.

Biogen (BIIB) Q1 Earnings Miss, Aduhelm Setback Leads to Rejig

by Zacks Equity Research

Biogen (BIIB) misses first-quarter estimates for earnings but beats the same for sales. Following no medicare beneficiary access to Aduhelm, Biogen initiates a cost-savings program.

Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) delivered earnings and revenue surprises of 0.96% and 66.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Sage Therapeutics, Inc. (SAGE): Can Its 11.8% Jump Turn into More Strength?

by Zacks Equity Research

Sage Therapeutics, Inc. (SAGE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.